2000
SkyePharma and PA Consulting Group announce inhalation collaboration agreement
-
27 March 2000
LONDON, England, 27 March, 2000 – SkyePharma PLC (LSE: "SKP"/Nasdaq: "SKYE") and PA Consulting Group announced today they have signed a collaboration agreement to develop jointly a range of non-CFC propelled metered dose asthma products. Under the terms of the agreement, SkyePharma will provide its expertise in non-CFC metered dose formulation and PA Consulting will provide its breath actuated metered inhaler device currently under development. The annual market size for asthma treatments is $4.5 billion and growing.
Michael Ashton, Chief Executive Officer of SkyePharma said: "PA Consulting’s metered inhaler device will significantly strengthen our existing portfolio of inhalation delivery technologies. More specifically, this collaboration will enhance our current products in development for the delivery of inhaled asthma drugs. SkyePharma’s leadership position in dry powder inhalation and its formulation expertise in non-CFC metered dose inhalers is widely recognised in the drug delivery industry. We are excited about the relationship with PA Consulting to extend this franchise."
PA's Executive Chairman, Jon Moynihan added: "This latest venture plays to our strengths and track record in innovation and technology, and offers tremendous opportunities for both organisations to pool expertise and develop better products for asthma sufferers. The combination of drug products and technology in this collaboration will lead to more effective ways of fighting respiratory illness, particularly among children, where getting the dose right the first time is very important."
For more information, please contact:
Notes to editors
SkyePharma PLC, one of the world’s leading drug delivery companies, develops and manufactures advanced drug delivery solutions. Its technologies include oral controlled release, injectable, inhalation and topical systems. For company information, visit SkyePharma on the World Wide Web at http://www.skyepharma.com
PA Consulting Group is a leading management, systems and technology consultancy, with a unique commitment to the integration of these capabilities. Established almost 60 years ago, and operating world wide from over 30 offices in some 20 countries, PA draws on the knowledge and experience of about 2,700 employees, whose skills span the initial generation of ideas and insights all the way through to detailed implementation, including:
-
Strategic management, and managing for shareholder value
-
Accelerating business growth, especially through innovation and technology
-
Improving business design and performance, including customer relationship management, enterprise-wide systems for the supply chain, and full e-business solutions
-
Mobilising human resources
-
Delivering change effectively, including projects and programmes
PA focuses on creating benefits for clients rather than merely proposing them, and this focus is supported by an outstanding implementation track record in every major industry and for governments around the world.
PA also develops leading-edge technology both for its clients and within its own portfolio of venture companies in areas ranging from software to wireless technology to life sciences.
We are proud that our clients say "PA makes it happen"
This press release may contain forward-looking statements regarding SkyePharma PLC and PA Consulting Group. Actual results may differ materially from those described in the press release as a result of a number of factors, including but not limited to the following: There can be no assurance that any product in the SkyePharma product pipeline will be successfully developed or manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of these products will be achieved. The Company undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.
|
